lifestyle.celebhomes.net
Home
Sample Page
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 1, 2026
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence
April 28, 2026
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
April 22, 2026
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
April 9, 2026
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
April 8, 2026
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
February 5, 2026
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
January 8, 2026
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
December 15, 2025
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
December 13, 2025
1
2
Next Page
→